» Articles » PMID: 32664275

Development of Folic Acid-Conjugated and Methylene Blue-Adsorbed Au@TNA Nanoparticles for Enhanced Photodynamic Therapy of Bladder Cancer Cells

Overview
Date 2020 Jul 16
PMID 32664275
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Photodynamic therapy (PDT) is a promising treatment for malignancy. However, the low molecular solubility of photosensitizers (PSs) with a low accumulation at borderline malignant potential lesions results in the tardy and ineffective management of recurrent urothelial carcinoma. Herein, we used tannic acid (TNA), a green precursor, to reduce HAuCl in order to generate Au@TNA core-shell nanoparticles. The photosensitizer methylene blue (MB) was subsequently adsorbed onto the surface of the Au@TNA nanoparticles, leading to the incorporation of a PS within the organic shell of the Au nanoparticle nanosupport, denoted as Au@TNA@MB nanoparticles (NPs). By modifying the surface of the Au@TNA@MB NPs with the ligand folate acid (FA) using NH-PEG-NH as a linker, we demonstrated that the targeted delivery strategy achieved a high accumulation of PSs in cancer cells. The cell viability of T24 cells decreased to 87.1%, 57.1%, and 26.6% upon treatment with 10 ppm Au@TNA/MB NPs after 45 min, 2 h, and 4 h of incubation, respectively. We also applied the same targeted PDT treatment to normal urothelial SV-HUC-1 cells and observed minor phototoxicity, indicating that this safe photomedicine shows promise for applications aiming to achieve the local depletion of cancer sites without side effects.

Citing Articles

Advances in smart nanotechnology-supported photodynamic therapy for cancer.

Li G, Wang C, Jin B, Sun T, Sun K, Wang S Cell Death Discov. 2024; 10(1):466.

PMID: 39528439 PMC: 11554787. DOI: 10.1038/s41420-024-02236-4.


Clinical insights into nanomedicine and biosafety: advanced therapeutic approaches for common urological cancers.

Fattahi M, Dehghani M, Paknahad S, Rahiminia S, Zareie D, Hoseini B Front Oncol. 2024; 14:1438297.

PMID: 39193389 PMC: 11347329. DOI: 10.3389/fonc.2024.1438297.


Efficacy and safety of photodynamic therapy for non-muscle-invasive bladder cancer: a systematic review and meta-analysis.

Li H, Long G, Tian J Front Oncol. 2023; 13:1255632.

PMID: 37860180 PMC: 10584312. DOI: 10.3389/fonc.2023.1255632.


Correction: Hsu et al. Development of Folic Acid-Conjugated and Methylene Blue-Adsorbed Au@TNA Nanoparticles for Enhanced Photodynamic Therapy of Bladder Cancer Cells. 2020, , 1351.

Hsu C, Cheng N, Liao M, Cheng T, Chiu Y Nanomaterials (Basel). 2023; 13(15).

PMID: 37570591 PMC: 10421507. DOI: 10.3390/nano13152233.


Nanomedicine for Combination Urologic Cancer Immunotherapy.

Tian Y, Liu Z, Wang J, Li L, Wang F, Zhu Z Pharmaceutics. 2023; 15(2).

PMID: 36839868 PMC: 9960671. DOI: 10.3390/pharmaceutics15020546.


References
1.
Yang Y, Hsu I, Cheng T, Wu W, Lee C, Li T . Off-Resonance SERS Nanoprobe-Targeted Screen of Biomarkers for Antigens Recognition of Bladder Normal and Aggressive Cancer Cells. Anal Chem. 2019; 91(13):8213-8220. DOI: 10.1021/acs.analchem.9b00775. View

2.
Liu R, Zhao J, Han G, Zhao T, Zhang R, Liu B . Click-Functionalized SERS Nanoprobes with Improved Labeling Efficiency and Capability for Cancer Cell Imaging. ACS Appl Mater Interfaces. 2017; 9(44):38222-38229. DOI: 10.1021/acsami.7b10409. View

3.
Kamat A, Hahn N, Efstathiou J, Lerner S, Malmstrom P, Choi W . Bladder cancer. Lancet. 2016; 388(10061):2796-2810. DOI: 10.1016/S0140-6736(16)30512-8. View

4.
Elmore S . Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007; 35(4):495-516. PMC: 2117903. DOI: 10.1080/01926230701320337. View

5.
Li N, Zhao P, Astruc D . Anisotropic gold nanoparticles: synthesis, properties, applications, and toxicity. Angew Chem Int Ed Engl. 2014; 53(7):1756-89. DOI: 10.1002/anie.201300441. View